Pivekimabsunirine

Drug

Related News

AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive growth

May 05, 2026

AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.

New Cancer Research Shows Promise in Blood Cancer, Prostate Cancer, and Ovarian Cancer Treatment

Mar 17, 2026

Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.